E. David Crawford, MD

Videos

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses genomic markers in prostate cancer.

Genomic Markers in Prostate Cancer

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses the utility of Prostate Health Index (PHI).

Since its introduction nearly twenty years ago, oncologists and researchers have been striving to improve PSA.

Prostate Health Index (PHI) looks at pro-PSA and seems to adequately predict prostate cancer, as well as aggressiveness of disease and outcome.

PHI score is typically used in men with high PSA.

The Utility of Prostate Health Index (PHI)

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

Each year in the U.S., 1.3-1.4 million biopsies are performed for prostate cancer, with only 240,000 leading to diagnoses

The need for a test to determine which men should be rebiopsied may have been answered by the ConfirmMDx test

Methylation tests look for DNA changes in normal tissue on a biopsy that potentially was around the cancer

If the test is negative and no genes are methylated, the physician is presented with a 90%-plus positive predictive value that the man does not have cancer. If the test is negative and the man does have cancer, it is typically low-grade and would not be treated anyway.

Rebiopsying for Prostate Cancer

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer. Crawford presented at the

7th Annual Interdisciplinary Prostate Cancer Congress&trade;

on defining candidates for active surveillance and modifying biopsy techniques.

The development of the bioptic gun has revolutionized the diagnosis of prostate cancer but has also created controversy.

PET and CT scans are a waste in localized prostate cancer; physicians are not worried about the disease spreading.

Low-risk patients are now being defined better with transperineal 3D mapping biopsies, which are done under the scrotum at 5 mm intervals.

Once 3D reconstruction of the prostate is completed, a physician can decide whether to treat with laser ablation, freezing, or definitive therapy.

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer.

Diagnosing Prostate Cancer: The Bioptic Gun, PET/CT Scans, and Mapping Biopsies

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses prostate cancer biopsies.

Normally cancers are diagnosed through PET and CT scans but prostate cancer is diagnosed through biopsies

Instead of relying solely on results of transrectal biopsies, patients who are deemed low-risk are given mapping biopsies

Mapping biopsies allow physicians to keep an eye on cancer growth in order to determine if further treatment is needed

E. David Crawford, MD | Authors

Articles

Genomic Markers in Prostate Cancer

The Utility of Prostate Health Index (PHI)

Rebiopsying for Prostate Cancer

Diagnosing Prostate Cancer: The Bioptic Gun, PET/CT Scans, and Mapping Biopsies

Prostate Cancer Biopsies